Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Cash from Investing Activities (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed Cash from Investing Activities for 7 consecutive years, with $346000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities rose 100.25% to $346000.0 in Q4 2025 year-over-year; TTM through Nov 2025 was $147.9 million, a 157.37% increase, with the full-year FY2025 number at $147.9 million, up 157.37% from a year prior.
  • Cash from Investing Activities was $346000.0 for Q4 2025 at Nurix Therapeutics, down from $50.5 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $71.5 million in Q2 2025 to a low of -$140.8 million in Q4 2024.
  • A 5-year average of -$6.1 million and a median of -$1.0 million in 2021 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: plummeted 2344.78% in 2021, then skyrocketed 1777.04% in 2022.
  • Nurix Therapeutics' Cash from Investing Activities stood at -$36.5 million in 2021, then soared by 250.61% to $55.0 million in 2022, then tumbled by 126.13% to -$14.4 million in 2023, then crashed by 879.73% to -$140.8 million in 2024, then surged by 100.25% to $346000.0 in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Cash from Investing Activities are $346000.0 (Q4 2025), $50.5 million (Q3 2025), and $71.5 million (Q2 2025).